$DUSA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in DUSA PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in DUSA PHARMACEUTICALS INC. Get notifications about new insider transactions in DUSA PHARMACEUTICALS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.57 | 305 | 1,394 | 1,693,093 | 1.7 M to 1.7 M (-0.02 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.57 | 195 | 891 | 898,372 | 898.6 K to 898.4 K (-0.02 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.23 | 122,000 | 516,060 | 1,693,398 | 1.8 M to 1.7 M (-6.72 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.23 | 78,000 | 329,940 | 898,567 | 976.6 K to 898.6 K (-7.99 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.41 | 15,250 | 67,253 | 1,815,398 | 1.8 M to 1.8 M (-0.83 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.41 | 9,750 | 42,998 | 976,567 | 986.3 K to 976.6 K (-0.99 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.37 | 122,000 | 533,140 | 1,830,648 | 2 M to 1.8 M (-6.25 %) |
| Mar 17 2011 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 4.37 | 78,000 | 340,860 | 986,317 | 1.1 M to 986.3 K (-7.33 %) |
| Mar 14 2011 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Payment of Exercise | F | 4.15 | 2,207 | 9,159 | 99,815 | 102 K to 99.8 K (-2.16 %) |
| Mar 14 2011 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Payment of Exercise | F | 4.15 | 7,430 | 30,835 | 395,101 | 402.5 K to 395.1 K (-1.85 %) |
| Mar 14 2011 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Payment of Exercise | F | 4.15 | 2,985 | 12,388 | 146,232 | 149.2 K to 146.2 K (-2.00 %) |
| Mar 14 2011 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Payment of Exercise | F | 4.15 | 2,517 | 10,446 | 71,582 | 74.1 K to 71.6 K (-3.40 %) |
| Mar 14 2011 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Payment of Exercise | F | 4.15 | 2,985 | 12,388 | 152,034 | 155 K to 152 K (-1.93 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Grant | A | 0.00 | 160,000 | 0 | 402,531 | 242.5 K to 402.5 K (+65.97 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Payment of Exercise | F | 3.95 | 10,319 | 40,760 | 242,531 | 252.9 K to 242.5 K (-4.08 %) |
| Mar 09 2011 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Option Exercise | M | 1.10 | 10,000 | 11,000 | 0 | |
| Mar 09 2011 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Option Exercise | M | 2.01 | 10,000 | 20,100 | 0 | |
| Mar 09 2011 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Buy | M | 1.10 | 10,000 | 11,000 | 42,500 | 32.5 K to 42.5 K (+30.77 %) |
| Mar 09 2011 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Buy | M | 2.01 | 10,000 | 20,100 | 32,500 | 22.5 K to 32.5 K (+44.44 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Grant | A | 0.00 | 45,000 | 0 | 105,146 | 60.1 K to 105.1 K (+74.82 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Payment of Exercise | F | 3.95 | 2,143 | 8,465 | 60,146 | 62.3 K to 60.1 K (-3.44 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Grant | A | 0.00 | 65,000 | 0 | 155,019 | 90 K to 155 K (+72.21 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Payment of Exercise | F | 3.95 | 3,334 | 13,169 | 90,019 | 93.4 K to 90 K (-3.57 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Grant | A | 0.00 | 45,000 | 0 | 102,022 | 57 K to 102 K (+78.92 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Payment of Exercise | F | 3.95 | 2,052 | 8,105 | 57,022 | 59.1 K to 57 K (-3.47 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Grant | A | 0.00 | 25,000 | 0 | 74,099 | 49.1 K to 74.1 K (+50.92 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Payment of Exercise | F | 3.95 | 1,358 | 5,364 | 49,099 | 50.5 K to 49.1 K (-2.69 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Grant | A | 0.00 | 65,000 | 0 | 149,217 | 84.2 K to 149.2 K (+77.18 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Payment of Exercise | F | 3.95 | 3,334 | 13,169 | 84,217 | 87.6 K to 84.2 K (-3.81 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Grant | A | 0.00 | 45,000 | 0 | 125,075 | 80.1 K to 125.1 K (+56.20 %) |
| Mar 08 2011 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Payment of Exercise | F | 3.95 | 2,143 | 8,465 | 80,075 | 82.2 K to 80.1 K (-2.61 %) |
| Aug 30 2010 | DUSA | DUSA PHARMACEUTICA ... | WURZER DAVID M | Director | Option Exercise | A | 2.34 | 15,000 | 35,100 | 15,000 | |
| Aug 30 2010 | DUSA | DUSA PHARMACEUTICA ... | WURZER DAVID M | Director | Buy | P | 2.35 | 4,500 | 10,575 | 5,000 | 500 to 5 K (+900.00 %) |
| Aug 30 2010 | DUSA | DUSA PHARMACEUTICA ... | WURZER DAVID M | Director | Buy | P | 2.35 | 400 | 939 | 500 | 100 to 500 (+400.00 %) |
| Aug 30 2010 | DUSA | DUSA PHARMACEUTICA ... | WURZER DAVID M | Director | Buy | P | 2.34 | 100 | 234 | 100 | 0 to 100 |
| Aug 30 2010 | DUSA | DUSA PHARMACEUTICA ... | Hondros Paul J. | Director | Option Exercise | A | 2.34 | 15,000 | 35,100 | 15,000 | |
| Aug 30 2010 | DUSA | DUSA PHARMACEUTICA ... | ALTOMARI ALFRED | Director | Option Exercise | A | 2.34 | 15,000 | 35,100 | 15,000 | |
| Aug 05 2010 | DUSA | DUSA PHARMACEUTICA ... | ALTOMARI ALFRED | Director | Buy | P | 2.52 | 2,000 | 5,040 | 2,000 | 0 to 2 K |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | LUFKIN RICHARD C | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | LESSER MARVIN E | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | HAFT JAY M | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | Casdin Alexander W. | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | BARTASH DAVID M | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jul 01 2010 | DUSA | DUSA PHARMACEUTICA ... | ABELES JOHN H | Director | Option Exercise | A | 2.15 | 10,000 | 21,500 | 10,000 | |
| Jun 09 2010 | DUSA | DUSA PHARMACEUTICA ... | LESSER MARVIN E | Director | Option Exercise | M | 1.10 | 15,000 | 16,500 | 0 | |
| Jun 09 2010 | DUSA | DUSA PHARMACEUTICA ... | LESSER MARVIN E | Director | Buy | M | 1.10 | 15,000 | 16,500 | 15,000 | 0 to 15 K |
| May 10 2010 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Payment of Exercise | F | 2.01 | 1,032 | 2,074 | 93,353 | 94.4 K to 93.4 K (-1.09 %) |
| May 10 2010 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Payment of Exercise | F | 2.01 | 1,044 | 2,098 | 59,074 | 60.1 K to 59.1 K (-1.74 %) |
| May 10 2010 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Payment of Exercise | F | 2.01 | 1,032 | 2,074 | 87,551 | 88.6 K to 87.6 K (-1.17 %) |
| May 10 2010 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Payment of Exercise | F | 2.01 | 1,177 | 2,366 | 50,457 | 51.6 K to 50.5 K (-2.28 %) |
| May 10 2010 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Payment of Exercise | F | 2.01 | 873 | 1,755 | 84,218 | 85.1 K to 84.2 K (-1.03 %) |
| May 10 2010 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Payment of Exercise | F | 2.01 | 873 | 1,755 | 62,289 | 63.2 K to 62.3 K (-1.38 %) |
| Mar 16 2010 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Payment of Exercise | F | 1.78 | 2,985 | 5,313 | 88,583 | 91.6 K to 88.6 K (-3.26 %) |
| Mar 16 2010 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Payment of Exercise | F | 1.78 | 2,638 | 4,696 | 60,118 | 62.8 K to 60.1 K (-4.20 %) |
| Mar 16 2010 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Payment of Exercise | F | 1.78 | 2,948 | 5,247 | 51,634 | 54.6 K to 51.6 K (-5.40 %) |
| Mar 16 2010 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Payment of Exercise | F | 1.78 | 2,638 | 4,696 | 63,162 | 65.8 K to 63.2 K (-4.01 %) |
| Mar 16 2010 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Payment of Exercise | F | 1.78 | 2,638 | 4,696 | 85,091 | 87.7 K to 85.1 K (-3.01 %) |
| Mar 16 2010 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Payment of Exercise | F | 1.78 | 3,215 | 5,723 | 94,385 | 97.6 K to 94.4 K (-3.29 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Option Exercise | A | 1.65 | 52,000 | 85,800 | 52,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Grant | A | 0.00 | 25,000 | 0 | 62,756 | 37.8 K to 62.8 K (+66.21 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Option Exercise | A | 1.65 | 55,000 | 90,750 | 55,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Grant | A | 0.00 | 27,000 | 0 | 87,729 | 60.7 K to 87.7 K (+44.46 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Option Exercise | A | 1.65 | 85,000 | 140,250 | 85,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Grant | A | 0.00 | 42,000 | 0 | 91,568 | 49.6 K to 91.6 K (+84.73 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Option Exercise | A | 1.65 | 30,000 | 49,500 | 30,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Grant | A | 0.00 | 15,000 | 0 | 54,582 | 39.6 K to 54.6 K (+37.90 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Option Exercise | A | 1.65 | 130,000 | 214,500 | 130,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Grant | A | 0.00 | 130,000 | 0 | 252,850 | 122.9 K to 252.9 K (+105.82 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Option Exercise | A | 0.00 | 55,000 | 0 | 55,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Grant | A | 0.00 | 27,000 | 0 | 65,800 | 38.8 K to 65.8 K (+69.59 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Option Exercise | A | 0.00 | 85,000 | 0 | 85,000 | |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Grant | A | 0.00 | 42,000 | 0 | 97,600 | 55.6 K to 97.6 K (+75.54 %) |
| Mar 08 2010 | DUSA | DUSA PHARMACEUTICA ... | HAFT JAY M | Director | Buy | P | 1.72 | 10,000 | 17,182 | 25,000 | 15 K to 25 K (+66.67 %) |
| Dec 18 2009 | DUSA | DUSA PHARMACEUTICA ... | ABELES JOHN H | Director | Buy | P | 1.30 | 20,000 | 25,960 | 77,000 | 57 K to 77 K (+35.09 %) |
| Dec 18 2009 | DUSA | DUSA PHARMACEUTICA ... | ABELES JOHN H | Director | Buy | P | 1.26 | 20,000 | 25,120 | 57,000 | 37 K to 57 K (+54.05 %) |
| Dec 18 2009 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Buy | P | 1.31 | 5,322 | 6,972 | 60,729 | 55.4 K to 60.7 K (+9.61 %) |
| Dec 18 2009 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Buy | P | 1.34 | 11,400 | 15,276 | 55,407 | 44 K to 55.4 K (+25.90 %) |
| Dec 18 2009 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Gift | G | 0.00 | 4,750 | 0 | 4,750 | 0 to 4.8 K |
| Dec 18 2009 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Gift | G | 0.00 | 4,750 | 0 | 122,850 | 127.6 K to 122.9 K (-3.72 %) |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Option Exercise | A | 1.10 | 10,000 | 11,000 | 10,000 | |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | LUFKIN RICHARD C | Director | Option Exercise | A | 1.10 | 10,000 | 11,000 | 10,000 | |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | LESSER MARVIN E | Director | Option Exercise | A | 1.10 | 15,000 | 16,500 | 15,000 | |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | HAFT JAY M | Director | Option Exercise | A | 1.10 | 10,000 | 11,000 | 10,000 | |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | Casdin Alexander W. | Director | Option Exercise | A | 1.10 | 10,000 | 11,000 | 10,000 | |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | BARTASH DAVID M | Director | Option Exercise | A | 1.10 | 10,000 | 11,000 | 10,000 | |
| Jul 01 2009 | DUSA | DUSA PHARMACEUTICA ... | ABELES JOHN H | Director | Option Exercise | A | 1.10 | 10,000 | 11,000 | 10,000 | |
| May 29 2009 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Payment of Exercise | F | 1.34 | 1,044 | 1,399 | 37,756 | 38.8 K to 37.8 K (-2.69 %) |
| Jun 26 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Buy | P | 0.90 | 274,104 | 246,694 | 1,952,648 | 1.7 M to 2 M (+16.33 %) |
| Jun 26 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Buy | P | 0.90 | 148,896 | 134,006 | 1,064,317 | 915.4 K to 1.1 M (+16.27 %) |
| May 29 2009 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Payment of Exercise | F | 1.34 | 1,032 | 1,383 | 49,568 | 50.6 K to 49.6 K (-2.04 %) |
| May 29 2009 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Payment of Exercise | F | 1.34 | 1,218 | 1,632 | 39,582 | 40.8 K to 39.6 K (-2.99 %) |
| May 20 2009 | DUSA | DUSA PHARMACEUTICA ... | Casdin Alexander W. | Director | Grant | A | 1.40 | 100,000 | 140,000 | 200,000 | 100 K to 200 K (+100.00 %) |
| May 20 2009 | DUSA | DUSA PHARMACEUTICA ... | Casdin Alexander W. | Director | Grant | A | 1.40 | 100,000 | 140,000 | 100,000 | 0 to 100 K |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Option Exercise | A | 1.22 | 75,100 | 91,622 | 75,100 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Grant | A | 0.00 | 37,600 | 0 | 50,600 | 13 K to 50.6 K (+289.23 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Option Exercise | A | 1.22 | 55,600 | 67,832 | 55,600 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Grant | A | 0.00 | 27,800 | 0 | 38,800 | 11 K to 38.8 K (+252.73 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Grant | A | 0.00 | 7,500 | 0 | 22,500 | 15 K to 22.5 K (+50.00 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Option Exercise | A | 1.22 | 55,600 | 67,832 | 55,600 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Grant | A | 0.00 | 27,800 | 0 | 40,800 | 13 K to 40.8 K (+213.85 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Option Exercise | A | 1.22 | 55,600 | 67,832 | 55,600 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Grant | A | 0.00 | 27,800 | 0 | 44,007 | 16.2 K to 44 K (+171.53 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | LUFKIN RICHARD C | Director | Grant | A | 0.00 | 7,500 | 0 | 19,600 | 12.1 K to 19.6 K (+61.98 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | HAFT JAY M | Director | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 0 to 15 K |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Option Exercise | A | 1.22 | 187,400 | 228,628 | 187,400 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Grant | A | 0.00 | 93,600 | 0 | 127,600 | 34 K to 127.6 K (+275.29 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Option Exercise | A | 1.22 | 75,100 | 91,622 | 75,100 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Grant | A | 0.00 | 37,600 | 0 | 55,600 | 18 K to 55.6 K (+208.89 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | ABELES JOHN H | Director | Grant | A | 0.00 | 7,500 | 0 | 12,500 | 5 K to 12.5 K (+150.00 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Option Exercise | A | 1.22 | 55,600 | 67,832 | 55,600 | |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Grant | A | 0.00 | 27,800 | 0 | 38,800 | 11 K to 38.8 K (+252.73 %) |
| Mar 17 2009 | DUSA | DUSA PHARMACEUTICA ... | BARTASH DAVID M | Director | Grant | A | 0.00 | 7,500 | 0 | 23,000 | 15.5 K to 23 K (+48.39 %) |
| Mar 13 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Buy | P | 1.21 | 162,000 | 196,020 | 1,678,544 | 1.5 M to 1.7 M (+10.68 %) |
| Mar 13 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Buy | P | 1.21 | 88,000 | 106,480 | 915,421 | 827.4 K to 915.4 K (+10.64 %) |
| Mar 03 2009 | DUSA | DUSA PHARMACEUTICA ... | Casdin Alexander W. | Director | Option Exercise | A | 1.27 | 15,000 | 19,050 | 15,000 | |
| Feb 25 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 1.08 | 130 | 140 | 1,516,544 | 1.5 M to 1.5 M (-0.01 %) |
| Feb 25 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 1.07 | 19,183 | 20,526 | 1,516,674 | 1.5 M to 1.5 M (-1.25 %) |
| Feb 25 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 1.08 | 70 | 76 | 827,421 | 827.5 K to 827.4 K (-0.01 %) |
| Feb 25 2009 | DUSA | DUSA PHARMACEUTICA ... | Flynn James E | 10% Owner | Sell | S | 1.07 | 10,465 | 11,198 | 827,491 | 838 K to 827.5 K (-1.25 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Sell | S | 1.14 | 579,994 | 661,193 | 1,451,647 | 2 M to 1.5 M (-28.55 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Sell | S | 1.20 | 16,948 | 20,371 | 2,031,641 | 2 M to 2 M (-0.83 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Sell | S | 1.48 | 8,700 | 12,911 | 2,048,589 | 2.1 M to 2 M (-0.42 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Sell | S | 1.50 | 19,600 | 29,400 | 2,057,289 | 2.1 M to 2.1 M (-0.94 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Sell | S | 1.54 | 18,400 | 28,244 | 2,076,889 | 2.1 M to 2.1 M (-0.88 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Sell | S | 1.45 | 38,400 | 55,795 | 2,095,289 | 2.1 M to 2.1 M (-1.80 %) |
| Dec 05 2008 | DUSA | DUSA PHARMACEUTICA ... | Becker Steven R | 10% Owner | Buy | P | 1.00 | 6,300 | 6,300 | 2,133,689 | 2.1 M to 2.1 M (+0.30 %) |
| Aug 26 2008 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Buy | P | 1.73 | 5,000 | 8,650 | 130,000 | 125 K to 130 K (+4.00 %) |
| Jul 01 2008 | DUSA | DUSA PHARMACEUTICA ... | MOLITEUS MAGNUS | Director | Option Exercise | A | 2.01 | 10,000 | 20,100 | 10,000 | |
| Aug 19 2008 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Grant | A | 2.00 | 5,000 | 10,000 | 83,250 | 78.3 K to 83.3 K (+6.39 %) |
| Jul 01 2008 | DUSA | DUSA PHARMACEUTICA ... | LUFKIN RICHARD C | Director | Option Exercise | A | 2.01 | 10,000 | 20,100 | 10,000 | |
| Jul 01 2008 | DUSA | DUSA PHARMACEUTICA ... | HAFT JAY M | Director | Option Exercise | A | 2.01 | 10,000 | 20,100 | 10,000 | |
| Jul 01 2008 | DUSA | DUSA PHARMACEUTICA ... | BARTASH DAVID M | Director | Option Exercise | A | 2.01 | 10,000 | 20,100 | 10,000 | |
| Jul 01 2008 | DUSA | DUSA PHARMACEUTICA ... | ABELES JOHN H | Director | Option Exercise | A | 2.01 | 10,000 | 20,100 | 10,000 | |
| May 13 2008 | DUSA | DUSA PHARMACEUTICA ... | SHULMAN D GEOFFREY | Chairman of the Boa ... | Option Exercise | A | 2.20 | 16,500 | 36,300 | 16,500 | |
| May 13 2008 | DUSA | DUSA PHARMACEUTICA ... | SHULMAN D GEOFFREY | Chairman of the Boa ... | Grant | A | 0.00 | 11,000 | 0 | 11,000 | 0 to 11 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Option Exercise | A | 2.20 | 16,500 | 36,300 | 16,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | Todisco Michael | Vice President, Con ... | Grant | A | 0.00 | 11,000 | 0 | 11,000 | 0 to 11 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Option Exercise | A | 2.20 | 19,500 | 42,900 | 19,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | ODell William F | Exec. VP Sales and ... | Grant | A | 0.00 | 13,000 | 0 | 13,000 | 0 to 13 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Option Exercise | A | 2.20 | 19,500 | 42,900 | 19,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | MARCUS STUART L | VP, Sc. Aff & CMO | Grant | A | 0.00 | 13,000 | 0 | 13,000 | 0 to 13 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Option Exercise | A | 2.20 | 16,500 | 36,300 | 16,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | LUNDAHL SCOTT L | VP, Regulatory Affa ... | Grant | A | 0.00 | 11,000 | 0 | 11,000 | 0 to 11 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Option Exercise | A | 2.20 | 28,500 | 62,700 | 28,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | Doman Robert F | President and CEO | Grant | A | 0.00 | 19,000 | 0 | 19,000 | 0 to 19 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Option Exercise | A | 2.20 | 19,500 | 42,900 | 19,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | CHRISTOPHER RICHARD | VP Finance & CFO | Grant | A | 0.00 | 13,000 | 0 | 13,000 | 0 to 13 K |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Option Exercise | A | 2.20 | 16,500 | 36,300 | 16,500 | |
| May 12 2008 | DUSA | DUSA PHARMACEUTICA ... | CAROTA MARK | Vice President, Ope ... | Grant | A | 0.00 | 11,000 | 0 | 11,000 | 0 to 11 K |